EXC — Exelon Corporation

The market has been cautious since Q2 2026 adjusted EPS of $0.43 missed consensus of $0.49, even though revenue of ~$6.0B beat by about 10% and management reaffirmed full-year 2026 EPS guidance of $2.81-$2.91. The stock is drifting below its 20-, 50-, and 200-day moving averages, and sell-side consensus sits at Hold with a mean target of $48.63 - implying modest upside but no urgency.

Revenue trends are stable-to-moderately growing: Q2 2026 revenue of $5.97B was +9.9% versus Q2 2025, Q1 2026 was +7.9%, Q3 2025 was +9.0%, while Q4 2025 was -1.1%. TTM operating margin improved modestly to 20.8% from ~20.0% a year earlier, and TTM net income rose from ~$2.65B to ~$2.78B. The Q2 2026 adjusted EPS miss looks like quarterly noise/weather/timing rather than the start of a structural decline; there is no revenue deceleration visible in the reported quarters.

Fair with a slight historical discount. As of 2026-08-27, trailing P/E is 16.04 versus the 5-year average of 17.99, and forward P/E on the $2.857 consensus 2026 EPS estimate is about 15.4. Price/sales of 1.79 is also below the 5-year average of 1.92. The 3.7% dividend yield plus 5-7% long-term EPS growth objective makes the stock look neither expensive nor deeply cheap; the PEG of 3.8 is not a meaningful utility metric.

At $43.96, the market is pricing in roughly 15.4x forward earnings, below EXC's own five-year average multiple, while earnings have been stable and guidance was reaffirmed. That suggests the stock is not pricing in much upside growth - it is more of a 'show me' situation waiting for another clean quarterly beat or favorable regulatory news. If management delivers the midpoint of guidance, the stock should drift toward the high-$40s; if regulatory outcomes disappoint, the low-$40s becomes the support test.

As of 2026-08-27, RSI-14 is 37.55, below neutral but not yet oversold. Price is -2.54% vs the 20-day, -4.57% vs the 50-day, and -4.42% vs the 200-day moving average, so the short- and medium-term trend is down/range-bound near the lower end of the 52-week range. Entry timing would improve on a stabilization above the 200-day or an RSI dip into the low-30s/high-20s; there is no confirmed reversal signal yet.

• Interest rates: A leveraged balance sheet (D/E 1.76) and $50.3B in long-term debt make EXC sensitive to higher-for-longer rates; defensive rotation can offset this when rate-cut expectations build.
• Data-center/electrification load growth: High-density data-center demand and electrification across its seven-state footprint support rate-base growth without relying on volatile commodity prices.
• Regulatory calendar: The BGE Maryland rate case and New Jersey storage filings will set the tone for allowed ROEs and capital-recovery speed; outcomes are binary for sentiment.
• Sector rotation: Utilities attract defensive flows during macro/market stress, but underperform when risk appetite returns; EXC's low beta of 0.40 makes it a portfolio stabilizer rather than a momentum trade.

• Q3 2026 earnings (late Oct/early Nov 2026): a beat or another miss against the $2.81-$2.91 full-year guidance will drive the near-term re-rating.
• Regulatory decisions and updates on the BGE rate case and Atlantic City Electric storage proposal.
• Execution of the $41.7B capex plan, especially the 16% transmission rate-base growth, which underpins the 5-7% EPS growth target.

• High leverage: debt-to-equity of 1.76 and negative quarterly free cash flow (-$255M in Q2 2026) leave limited equity cushion if regulatory recoveries slow or rates rise.
• Regulatory disallowance: rate cases can produce lower allowed ROEs or delayed cost recovery, directly hitting the earnings growth model.
• Earnings/multiple disappointment: the Q2 adjusted EPS miss shows consensus can be missed; a full-year miss would likely pressure the multiple below 15x and push the stock toward the low end of the range.

EXC is a well-run regulated utility with a defensive 3.7% yield, a 5-7% long-term EPS growth target, and a valuation below its own five-year average. It is not a high-conviction buy right now because of high leverage, the recent adjusted EPS miss, and a still-unresolved regulatory backdrop; but at $43.96 the risk/reward is balanced, making it a reasonable hold/accumulate for income-oriented investors rather than a growth story.

I applied a 17.0x justified P/E to consensus 2026 EPS of $2.857, a modest discount to EXC's 5-year average P/E of 17.99 to reflect its high leverage and modest ROIC. That yields $48.57, roughly in line with the analyst consensus target of $48.63, confirming that the current $43.96 price embeds a small margin of safety.